Eli Lilly (LLY) said Friday that new results showed that 50% of patients with moderate-to-severe atopic dermatitis, or eczema, achieved completely clear skin at three years after receiving single monthly maintenance injection of Ebglyss.
The patients were among the Ebglyss week 16 responders from the monotherapy trials, the company said.
Eli Lilly also said 87% achieved or maintained "almost-clear" skin at three years with Ebglyss based on data from a long-term extension study.
Ebglyss was approved by the US Food and Drug Administration in 2024 as a first-line monotherapy biologic treatment option after topical prescription therapies.
The company also said that based on additional studies, Ebglyss improved symptoms such as itch, skin pain and sleep loss due to itch.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。